Uncategorized

New Releases from NCBI BookshelfLoncastuximab tesirine for treating relapsed or refractory diffuse large B-cell lymphoma and high-grade B-cell lymphoma after 2 or more systemic treatments.Loncastuximab tesirine for treating relapsed or refractory diffuse large B-cell lymphoma and high-grade B-cell lymphoma after 2 or more systemic treatments.

Leave a Comment / Uncategorized / admin

Post Content

New Releases from NCBI BookshelfBelumosudil for treating chronic graft-versus-host disease after 2 or more systemic treatments in people 12 years and over.Belumosudil for treating chronic graft-versus-host disease after 2 or more systemic treatments in people 12 years and over.

Leave a Comment / Uncategorized / admin

Post Content

New Releases from NCBI BookshelfEnhancing the Resilience of Health Care and Public Health Critical Infrastructure: Proceedings of a Workshop—in Brief.Enhancing the Resilience of Health Care and Public Health Critical Infrastructure: Proceedings of a Workshop—in Brief.

Leave a Comment / Uncategorized / admin

When disaster strikes, critical infrastructure failures can follow – from loss of power and water to failures of information technology

New Releases from NCBI BookshelfEpcoritamab for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic treatments.Epcoritamab for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic treatments.

Leave a Comment / Uncategorized / admin

Post Content

New Releases from NCBI BookshelfSebelipase alfa for treating Wolman disease.Sebelipase alfa for treating Wolman disease.

Leave a Comment / Uncategorized / admin

Post Content

New Releases from NCBI BookshelfDupilumab for treating moderate to severe prurigo nodularis.Dupilumab for treating moderate to severe prurigo nodularis.

Leave a Comment / Uncategorized / admin

Post Content

New Releases from NCBI BookshelfMomelotinib for treating myelofibrosis-related splenomegaly or symptoms.Momelotinib for treating myelofibrosis-related splenomegaly or symptoms.

Leave a Comment / Uncategorized / admin

Post Content

New Releases from NCBI BookshelfSetmelanotide for treating obesity and hyperphagia in Bardet-Biedl syndrome.Setmelanotide for treating obesity and hyperphagia in Bardet-Biedl syndrome.

Leave a Comment / Uncategorized / admin

Post Content

New Releases from NCBI BookshelfEtrasimod for treating moderately to severely active ulcerative colitis in people aged 16 and over.Etrasimod for treating moderately to severely active ulcerative colitis in people aged 16 and over.

Leave a Comment / Uncategorized / admin

Post Content

New Releases from NCBI BookshelfMultiple Symptoms Study 3 – An extended-role general practitioner clinic for patients with persistent physical symptoms: a Randomised Controlled Trial [Internet].Multiple Symptoms Study 3 – An extended-role general practitioner clinic for patients with persistent physical symptoms: a Randomised Controlled Trial [Internet].

Leave a Comment / Uncategorized / admin

People with multiple and persistent physical symptoms have impaired quality of life and poor experiences of health care. We aimed